Phase II study of edatrexate in advanced head and neck cancer : a Southwest Oncology Group study

Fifty-two patients with persistent, recurrent and/or metastatic squamous cell cancer of the head and neck were treated with weekly edatrexate, 80 mg/m2. Nine patients had received previous adjuvant or neoadjuvant chemotherapy. Of the 46 eligible patients, two complete responses and one partial respo...

Full description

Saved in:
Bibliographic Details
Published in:Investigational new drugs 1994-01, Vol.12 (4), p.341-344
Main Authors: KUEBLER, J. P, BENEDETTI, J, SCHULLER, D. E, ENSLEY, J, GRUNBERG, S. M, MUIRHEAD, M. J, RICHERT-BOE, K. E, MARSHALL, M. E
Format: Article
Language:English
Subjects:
Adult
Aged
Aminopterin - adverse effects
Aminopterin - analogs & derivatives
Aminopterin - therapeutic use
Antineoplastic agents
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - secondary
Chemotherapy
Female
Head and Neck Neoplasms - drug therapy
Humans
Male
Medical sciences
Middle Aged
Neoplasm Recurrence, Local - drug therapy
Pharmacology. Drug treatments
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fifty-two patients with persistent, recurrent and/or metastatic squamous cell cancer of the head and neck were treated with weekly edatrexate, 80 mg/m2. Nine patients had received previous adjuvant or neoadjuvant chemotherapy. Of the 46 eligible patients, two complete responses and one partial response were observed (6%, 95% confidence interval of 1-18%). The most common toxicities were myelosuppression and mucositis, but dermatologic toxicity was also observed in 25% of patients. Edatrexate appears to have limited activity in advanced head and neck cancer.
ISSN:0167-6997
1573-0646
DOI:10.1007/BF00873052